Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2013-09-09 Regulatory Filings
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text describes presentations of clinical study data at a medical congress and references exhibits containing detailed study posters. There is no indication of a full annual or quarterly financial report, audit report, or earnings release. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing reporting other events (clinical study presentations) and includes exhibits. The length is about 5,518 characters, which is consistent with a typical 8-K filing. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2013-09-09 English
THERAVANCE INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an event related to the FDA posting briefing documents for an advisory committee meeting concerning a drug application. It does not contain financial statements or detailed financial analysis. The document is short (3012 characters) and serves as an announcement of an event rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-09-06 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 5, 2013. It announces a conference call by management to discuss results from a Phase 2b study of a drug. The document includes a slide presentation as an exhibit. The text explicitly states that the information is being furnished and shall not be deemed filed for certain regulatory purposes, indicating this is a current report rather than a full financial report. The content focuses on a conference call and presentation of study results, which aligns with a Call Transcript or Investor Presentation. However, since the document is an 8-K announcing a conference call and includes a slide presentation, it fits best as an Investor Presentation (IP). The document length is 3700 characters, which is short but contains the presentation itself as an exhibit, not just an announcement of a report. Therefore, the classification is Investor Presentation (IP).
2013-09-05 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 4, 2013. It announces the results of a Phase 2b study for a drug and mentions a press release and a conference call. The document is short (3014 characters) and primarily serves as an announcement of information rather than containing detailed financial data or full report content. It includes a press release as an exhibit and references a conference call to discuss results. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain comprehensive financial statements or detailed report content. It is not an earnings release (ER) because it is about clinical trial results, not financial results. It is not a call transcript (CT) because the call is scheduled for the next day and the transcript is not included. Therefore, the best classification is Regulatory Filings (RNS).
2013-09-04 English
FORM 4 -
Director's Dealing
2013-08-23 English
FORM 4 -
Director's Dealing
2013-08-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.